Chiasma, Inc. (CHMA)
| Market Cap | 230.22M |
| Revenue (ttm) | 1.11M |
| Net Income (ttm) | -74.78M |
| Shares Out | 52.23M |
| EPS (ttm) | -1.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $3.98 |
| Previous Close | $3.98 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 3.80 |
| Day's Range | 3.70 - 4.05 |
| Day's Volume | 8,557,904 |
| 52-Week Range | 2.77 - 7.75 |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Chiasma, Inc. (NASDAQ: CHMA) to Amryt Pharma plc is fair to Chiasma shareholders. Und...
Chiasma (CHMA) delivered earnings and revenue surprises of -63.33% and 6.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Amryt Pharma PLC (LON:AMYT NASDAQ:AMYT) is to merge with fellow Nasdaq-listed biotech Chiasma Inc (NASDAQ:CHMA) through an all-share deal that will create a leading specialist in rare and orphan diseas...
Amryt Pharma PLC (LON:AMYT NASDAQ:AMYT) is to merge with fellow Nasdaq-listed biotech Chiasma Inc (NASDAQ:CHMA) through an all-share deal that will create a leading specialist in rare and orphan diseas...
Penny stocks are making big waves on Cinco De Mayo; are these 3 worth watching? The post Hot Penny Stocks to Buy?
Amryt Pharma (NASDAQ: AMYT) has agreed to acquire Chiasma Inc (NASDAQ: CHMA) in an all-stock combination. Each Chiasma shares will be exchanged for 0.396 Amryt American Depositary Shares, each represent...
Announced agreement to merge with Amryt
- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline
--93% of all patients who enrolled as a responder to MYCAPSSA ® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was ge...
Chiasma Inc (NASDAQ: CHMA) has announced new data from the MPOWERED Phase 3 trial of Mycapssa as the first oral therapy to treat acromegaly. Chiasma presented the data at the Endocrine Society's annual ...
--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related...
-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biop...
Chiasma (CHMA) delivered earnings and revenue surprises of 8.57% and -17.75%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Appointment provides extensive commercial-stage public company financial leadership experience Appointment provides extensive commercial-stage public company financial leadership experience
MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers
The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts i...
Chiasma launched its first product, Mycapssa, on August 31, 2020. Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously injection-only...
Today, we revisit Chiasma for the first time in over a year. This promising small-cap name recently posted some encouraging trial results and has seen a big recent insider purchase by its CEO.
NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral ...
NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral ...
91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled phase of the non-inferiority trial
NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral ...
Chiasma's (CHMA) CEO Raj Kannan on Q3 2020 Results - Earnings Call Transcript
L aunched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September
NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to peo...
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal Financial O...
NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to re...
Chiasma advances U.S. commercial launch originally planned for fourth quarter Chiasma advances U.S. commercial launch originally planned for fourth quarter
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to red...
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q2 2020 Results - Earnings Call Transcript
MYCAPSSA® U.S. commercial launch planned for the fourth quarter
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was mai...
The company announced the pricing of a public offering of common stock.
NEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietar...
Chiasma (CHMA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietar...
Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved
Investors need to pay close attention to Chiasma (CHMA) stock based on the movements in the options market lately.
MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q1 2020 Results - Earnings Call Transcript
NEEDHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associa...
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2019 Results - Earnings Call Transcript
FDA sets PDUFA date of June 26, 2020
MYCAPSSA ® NDA resubmitted to FDA; PDUFA decision expected mid-2020
NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic dise...
WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic dise...
About CHMA
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the ma... [Read more...]
| Industry Biotechnology | IPO Date Jul 16, 2015 |
| CEO Raj Kannan | Employees 85 |
| Stock Exchange NASDAQ | Ticker Symbol CHMA |
Analyst Forecasts
According to 5 analysts, the average rating for Chiasma stock is "Strong Buy." The 12-month stock price forecast is 13.60, which is an increase of 241.71% from the latest price.